GlassScriptPhysician profile
John J Kelly
NPI 1659303634
$3,659.19
in general payments reported to CMS, 2019-2025
32 companies · $94.31 in 2025
The $94.31 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $119 · 2021: $149 · 2022: $1,473 · 2023: $103 · 2024: $65.70 · 2025: $94.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $2,134.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $242.08 | 2019-2023 | |
| Cook Medical LLC | $144.07 | 2019 | |
| Akcea Therapeutics, INC. | $129.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.09 | 2019-2022 | |
| Amgen INC. | $79.43 | 2019-2021 | |
| Bolton Medical INC | $78.95 | 2021 | |
| Pfizer INC. | $77.42 | 2019-2024 | |
| Amarin Pharma, INC. | $61.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $56.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $53.31 | 2019 | |
| Boston Scientific Corporation | $43.71 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.56 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.69 | 2019-2023 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $36.80 | 2024 | Arcalyst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $29.62 | 2019 | |
| Esperion Therapeutics, INC. | $28.17 | 2021-2023 | Nexletol |
| Arbor Pharmaceuticals, INC. | $24.66 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $24.52 | 2025 | Assure Wcd |
| Heartflow, INC. | $24.06 | 2023 | Ffrct |
| Abbott Laboratories | $22.85 | 2025 | Triclip |
| Lundbeck LLC | $21.36 | 2019 | |
| Edwards Lifesciences Corporation | $19.34 | 2025 | |
| Medtronic Vascular, INC. | $18.23 | 2019 | |
| W. L. Gore & Associates, INC. | $15.68 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.44 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.07 | 2025 | Ultomiris |
| Siemens Medical Solutions USA, INC. | $13.53 | 2025 | Syngo.Via, Syngo Dynamics |
| Kowa Pharmaceuticals America, INC. | $12.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Daiichi Sankyo INC. | $11.60 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.59 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.